Liana, diagnosed with hATTR amyloidosis
and her daughter Gabriella (Brazil)
$
0
in out-of-pocket costs for a majority of patients
>
0
%
of U.S. residents with confirmed access across payer types
0
+
countries where patients can access our therapies by way of direct or distributor infrastructure
0
+
patients enrolled in Alnylam Assist®
Sustainable Value and Significant Impact
We believe it is our responsibility to push the boundaries of scientific discovery, clinical development, and delivery to fuel significant, sustainable patient impact.
- We make decisions for as many people who can benefit from the potential of our medicines.
- We believe we have an obligation to commit resources that promote diversity of clinical trials, ensure equitable access, and empower individuals with choice.
- We act with purposeful urgency to expand our geographic reach and enable sustainable access pathways.
$0
in out-of-pocket costs for a majority of patients
~90%
of patients have first-line access to AMVUTTRA®
>95%
of U.S. residents with confirmed access to our therapies across commercial, Medicare, Medicaid, and other government payers
70+
countries where patients can access our therapies by way of direct or distributor infrastructure
960+
patients who have received Alnylam therapeutics under compassionate use
~90%
of patients can receive AMVUTTRA® treatment within ~10 miles of where they live
93%
of EU countries have access to at least one of our therapies
Connecting to Achieve Better Outcomes
We believe that together with partners in the healthcare ecosystem, we can reduce barriers to our medicines to improve outcomes for all stakeholders in the patient journey – most importantly, for the patients who may benefit from them.
- We believe biopharmaceutical companies must address access and improve outcomes from the time of drug discovery.
- We recognize that a patient’s ability to access and afford our medicines is complex, and we commit to continuing our legacy of value-centric solutions.
- We seek to remove barriers within our control to enable patients to receive care in convenient settings.
31
patient voice inclusion interviews in ten countries
4,000+
U.S. patients enrolled in Alnylam Assist®
6,300+
personalized patient touchpoints by Patient Education Liaison (PEL) team
55
55 value-based agreements signed with U.S. payers across therapies
5,200+
patients participating in clinical trials for our therapies
Proactive and Accountable
We believe that biopharmaceutical companies play a critical role in the patient’s journey to accessing innovative therapeutic options and should be accountable for progress.
- We aim to create compliant solutions that are designed to empower patients to feel confident throughout their treatment journey.
- We advocate for policies, technology and evidence to promote innovation and reduce the time for approved treatments to reach patients.
- We partner with others for the sake of science and the good of patients, committed to the continuous evolution that began before we launched the world’s first RNAi therapeutic and will endure for as long as we are Alnylam.
134,000+
samples genotyped through Alnylam Act® or GeneActTM since the program began
208
patient advocacy events supported worldwide
98
patient advocacy groups supported worldwide
15
U.S. outcome initiatives for patients with hATTR-PN and ATTR-CM implemented with large health systems
Patient Access Programs Supporting Patients Throughout the Treatment Journey
Through various programs, we provide patients with access to diagnostic resources and genetic testing with the goal of removing barriers for patients to access to our commercially available therapies. In addition, we enable access to our investigational drugs for treatment outside clinical trials when no comparable or satisfactory alternative therapy options are available.
Our key programs include:
- Alnylam Act® offers eligible patients in the U.S., Canada, and Brazil no-charge, third-party genetic testing and counseling.*
- GeneAct™ offers third-party genetic testing in selected countries across Europe and Middle East.*
- Alnylam’s Compassionate Use Policy outlines the circumstances in which we will consider providing treatment for an individual patient outside a clinical trial. We evaluate all requests in a fair and equitable manner.
- Since Alnylam’s first commercial launch in 2018, Alnylam Assist® has supported patients throughout their journey, offering best-in-class patient support services. Staffed by Alnylam employees solely dedicated to supporting patients and providers in our disease states, this model has enabled our team to develop a deep understanding of the patient journey and expertly manage treatment initiation, access and reimbursement, and financial assistance.
Statistics reflect Alnylam Data on File
* Healthcare professionals or patients who use these programs have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Alnylam product
You will be redirected to an external site that may include social media, event registration, or other third-party content related to Alnylam.
Please note that these external sites have their own terms of service and privacy policies, which may differ from those of Alnylam.
Proceed to Site